Since 1987 when zopiclone (somnosan, ximovan) was introduced into clinical practice, extensive evaluations have shown that some rebound changes can be detected in healthy individuals. In patients with insomnia more than 20 studies have assessed rebound. Rebound can be found in such patients, but is usuallymore frequent and present in greater intensity in comparison groups given triazolam.

Studies in the elderly have been carefully reviewed by Soldatos and his colleagues. Some deterioration in the soundness of sleep has been detected but the amount of rebound insomnia following zopiclone (somnosan, ximovan) discontinuation is relatively weak. Although one would certainly expect rebound in a hypnotic with a half-life of around 5 h, the frequency and severity of such rebound seems definitely less than those observed with comparative benzodiazepines such as triazolam and temazepam. Read the rest of this entry »

Benzodiazepines became widely available for medical purposes in the 1960s and replaced barbiturates in treatments of many conditions. Benzodiazepines proved themselves less prone to abuse than barbiturates, in addition to being safer—accidental overdose is unlikely because the amount needed for a medical effect is so much smaller than a poisonous amount. In addition to reducing anxiety, benzodiazepines may improve quality of sleep—from fighting insomnia to eliminating sleepwalking. This class of drugs is also used to calm people and to treat convulsions. Some users experience mild euphoria. Read the rest of this entry »